Media Articles Related to Combivent (Ipratropium / Albuterol)
COPD (Chronic Obstructive Pulmonary Disease)
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2015.11.04]
Title: COPD (Chronic Obstructive Pulmonary Disease)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/4/2015 12:00:00 AM
COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.20]
Title: COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Created: 6/18/2010 12:20:00 PM
Last Editorial Review: 11/20/2013 12:00:00 AM
COPD (Chronic Obstructive Pulmonary Disease) Quiz
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2012.11.06]
Title: COPD (Chronic Obstructive Pulmonary Disease) Quiz
Category: MedicineNet Quiz
Created: 10/8/2012 5:18:00 PM
Last Editorial Review: 11/6/2012 5:24:02 PM
New research method questions traditional efficacy trial model
Source: Respiratory / Asthma News From Medical News Today [2016.09.06]
Traditional efficacy trials have limited relevance to everyday clinical practice and should be changed, according the authors of a new study into chronic obstructive pulmonary disease (COPD)...
Published Studies Related to Combivent (Ipratropium / Albuterol)
Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. [2010.08]
We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study...
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.12]
BACKGROUND: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination... CONCLUSION: Patients previously maintained on the ipratropium/albuterol combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours and superior bronchodilation during early morning hours.
Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. [2009.11]
BACKGROUND: The objective of this study was to determine whether a combination of nebulized albuterol and ipratropium with warmed humidified oxygen would be more beneficial when compared to the same combination with humidified oxygen at room temperature. Albuterol alone was tested in the same settings... CONCLUSION: Our study shows that warmed humidified oxygen given along with the combination of nebulized albuterol and ipratropium is more beneficial for pediatric patients having an acute exacerbation of bronchial asthma in the winter months when compared to nebulized albuterol alone with warmed humidified oxygen, nebulized albuterol alone with room temperature humidified oxygen, or a combination of nebulized albuterol and ipratropium with room temperature humidified oxygen.
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
BACKGROUND: The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components. OBJECTIVE: The aim of this study was to confirm the findings of a previous study that compared the efficacy of a combination of 2 short-acting bronchodilators with the use of an inhaled corticosteroid and a long-acting beta-agonist in the treatment of COPD... CONCLUSION: In this 8-week study, subjects with moderate to severe COPD experienced greater improvements in lung function and symptom measures with FSC than with IB/ALB.
Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. [1997.08]
BACKGROUND: Routine addition of ipratropium bromide to beta-agonist therapy in acute asthma is of uncertain benefit. OBJECTIVE: This study was carried out to evaluate: (1) whether nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent) confers additional bronchodilation over nebulized salbutamol (2.5 mg) alone in patients with acute asthma and (2) whether adjustment for prognostic indicators of outcome influences any benefit seen with ipratropium... CONCLUSION: A single dose of nebulized Combivent confers additional bronchodilation over salbutamol alone (p < 0.05) in acute asthma. Patients who exhibited most benefit from the addition of ipratropium were those who had consumed the least inhaled beta-agonist before presentation, not those with the most severe asthma.
Clinical Trials Related to Combivent (Ipratropium / Albuterol)
Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Terminated]
To compare the long-term (one-year) bronchodilator efficacy and safety of COMBIVENT
hydrofluoroalkane (HFA) Inhalation Aerosol to COMBIVENT chlorofluorocarbon (CFC) Inhalation
Aerosol and Placebo formulations of each in patients with COPD. In addition, steady state
pharmacokinetics over one dosing interval following four weeks of therapy will be
Ipratropium Bromide/Salbutamol Delivered by the Respimat« Inhaler Compared to Ipratropium Bromide Respimat«, COMBIVENT« Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease [Completed]
The primary objective of this study was to compare the long-term (12-week) bronchodilator
efficacy and safety of ipratropium bromide / salbutamol combination administered by the
Respimat« 40 mcg / 200 mcg (one inhalation q. i.d.) to COMBIVENT Inhalation Aerosol (two
inhalations q. i.d.), ipratropium bromide Respimat« (one inhalation q. i.d.) and Placebo
formulations of each in patients with Chronic Obstructive Pulmonary Disease (COPD). An
additional objective was to show the superiority of Combivent Respimat as compared to
ipratropium bromide (40 mcg) Respimat. Steady state pharmacokinetics over one dosing
interval following four weeks of therapy were also characterized.
A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Completed]
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA)
inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two
puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC)
inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The
dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be
Combivent´┐Ż HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease) [Terminated]
Study to evaluate the safety of combivent delivered in two different formulations
(hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI),
using a cumulative dose response model in patients with COPD.
Safety and Tolerability of COMBIVENT« HFA as Compared to COMBIVENT« CFC and Placebo HFA in Healthy Male and Female Subjects [Completed]
Reports of Suspected Combivent (Ipratropium / Albuterol) Side Effects
Drug Ineffective (64),
Drug Effect Decreased (16),
Chronic Obstructive Pulmonary Disease (11),
Throat Irritation (10),
DRY Mouth (9), more >>